Showing 1152 Results
Employers Identify Best Practices for High-Deductible Health Plans in New Research From the National Pharmaceutical Council and Gallagher Research & Insights
Webinar highlights new research and steps employers can take to implement better HDHP designs.
High-Deductible Health Plans: Good Practices for Employers
Research highlights good practices for designing high-deductible health plans to help enrollees better maximize the value of their benefits.
Employers Identify Good Practices for High-Deductible Health Plans
Employers can design a smarter high-deductible health plans by following good practices identified in NPC research.
NPC Chair Shares His Outlook for an Energized Organization
In his first post as Board chair, Mallinckrodt Pharmaceuticals' Dr. Steven Romano says NPC is in a strong position to lead health policy debates through new leadership, dedicated staff experts and an…
Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries
Proposals seeking to improve access for Medicare beneficiaries should ensure that patients are better able to get the medicines their doctors say they need.
E.V.I.dently® | January 2022
In this issue: We offer a new resource on the myth of the "average" patient, outline key challenges in value assessment and health technology assessment, and highlight two upcoming webinars.
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2023
NPC offers research-based comments to improve patient access to care and health equity.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
How Reforms Can Enable Payment Innovation That Drives Value
This NPC study models the effects of recent and proposed payment reforms related to CMS' best price reporting rules and sheds light on which approaches may encourage the adoption of value-based…
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and continued…
How the Myth of Average Persists in Health Benefits
People are different and their health needs vary. Though differences among patients are common, these differences aren’t always considered in treatment and coverage decisions.
The Myth of Average: Why Individual Patient Differences Matter
NPC's "The Myth of Average" explores how patients, health care providers, insurers, and other decision-makers can better consider individual patient differences when navigating the complexities of…
Kimberly Westrich Talks Benefit Design with AJMC
NPC's Vice President of Health Services Research, Kimberly Westrich, MA, discusses how the healthcare system can incentivize high-value care.
NPC in Chain Drug Review: Fostering a More Informed Drug Pricing Conversation
To kick off the new year, NPC's John M. O’Brien writes in Chain Drug Review about the need for a more informed public discussion about the role that prescription drugs play in our health care system…
National Pharmaceutical Council Appoints Dr. Sharon Phares as Chief Scientific Officer
NPC announced the appointment of Sharon Phares, PhD, MPH, as Chief Scientific Officer.
Achieving “Fair Access” Requires Better Benefit Design
An Institute for Clinical and Economic Review report acknowledges that patients are still facing barriers to needed treatments as a result of their health benefit design.
The Patient’s Medication Access Journey: A Conceptual Framework Focused Beyond Adherence
The Pharmacy Quality Alliance, with support from NPC, developed a framework that defines a patient’s medication access journey and characterizes barriers frequently encountered while seeking…
E.V.I.dently® | November 2021
In this issue: Explore the pitfalls in the most recent drug pricing deal, regulation that's led to improvements in employee benefits and keys to improving equity in health coverage.
NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients
In a commentary for RealClearPolicy, NPC’s John M. O’Brien explains how the drug pricing deal in the Build Back Better Act could create harmful unintended consequences for patient health and the…